EverHint – Dip Bounce V2 (Reclaim) – Top 10 Signals for Oct 27, 2026
Excerpt: 10 signals (from 47 total). Healthcare leads (18). price range $12-$309. 5 with insider selling.
What This Signal Is
Production-ready dip-bounce strategy using reclaim pattern with Phase 2 market regime filters. Improved win rate from 40.42% (V1) to 50.18% (V2) with VIX and record high filters.
Entry Criteria:
- Minimum dip: 3.3% (open to intraday low)
- Minimum bounce: 1.0% from low
- Net change range: -2.0% to +0.3%
- Price above SMA(200)
- Minimum ADV: $40M
Holding period: 1-5 days | Risk level: Medium
Market Context
The VIX sitting at 17.52 — down nearly 5% on the session — signals a meaningful pullback in implied volatility, which creates a favorable backdrop for dip-bounce strategies. Lower volatility environments tend to compress intraday price swings, which can benefit reclaim-style setups by reducing the risk of false breakouts and allowing price to consolidate more cleanly around key technical levels before confirming a move. That said, a VIX in the mid-to-upper teens still carries enough uncertainty to keep traders honest, so entries on reclaim signals warrant disciplined risk management rather than aggressive sizing.
The broader tape is broadly constructive, with the Nasdaq leading at +1.18% while the Dow barely budged at +0.03%. This divergence points to a growth-and-tech-tilted risk appetite rather than a broad-based rally, suggesting that capital is rotating selectively rather than lifting all boats. For dip-bounce reclaim signals, this kind of environment rewards names that align with the prevailing momentum theme — weak or defensive sectors may see reclaim attempts fail to follow through without broader participation.
Healthcare emerging as the top signal sector is a notable rotation cue. Healthcare tends to attract flows when investors seek a blend of defensive stability and growth optionality, which fits the current mixed market tone — strong in growth names but cautious in cyclicals. Dip-bounce reclaims in Healthcare may benefit from this underlying bid, as sector tailwinds can provide the sustained buying pressure needed to confirm a reclaim and hold above key technical levels rather than fading back into the prior range.
📊 Signals (10 of 47 total)
Ranked by dip magnitude (highest first)
| # | Ticker | Company | Sector | Price | Score | Insider | MCap |
|---|---|---|---|---|---|---|---|
| 1 | BHVN | Biohaven Ltd. | Healthcare | $15.29 | 0.23 | — | $2.3B |
| 2 | RHI | Robert Half Inc. | Industrials | $41.96 | 0.21 | — | $4.3B |
| 3 | QCOM | QUALCOMM Incorporated | Technology | $184.17 | 0.20 | Sell -$54,033 | $196.7B |
| 4 | TXN | Texas Instruments Inco... | Technology | $308.91 | 0.20 | — | $282.1B |
| 5 | TEM | Tempus AI, Inc. | Healthcare | $72.15 | 0.18 | — | $12.8B |
| 6 | TWST | Twist Bioscience Corpo... | Healthcare | $159.85 | 0.17 | — | $10.5B |
| 7 | TXG | 10x Genomics, Inc. | Healthcare | $78.02 | 0.17 | — | $10.2B |
| 8 | NEO | NeoGenomics, Inc. | Healthcare | $17.27 | 0.17 | — | $2.2B |
| 9 | NEOG | Neogen Corporation | Healthcare | $12.47 | 0.17 | — | $2.7B |
| 10 | AZTA | Azenta, Inc. | Healthcare | $39.08 | 0.17 | — | $1.7B |
Recent Headlines
AZTA (Azenta, Inc.)
- ROSEN, LEADING INVESTOR COUNSEL, Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA
NEOG (Neogen Corporation)
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neogen Corporation - NEOG
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/
📢 Support the project by liking, sharing, or subscribing — it helps more readers discover these signals.